Cargando…
Commissioning of a Versa HD(TM) linear accelerator for three commercial treatment planning systems
In a mixed‐vendor radiation oncology environment, it is advantageous if the department's treatment planning system (TPS) supports the linear accelerators of different vendors. In this publication beam data collection and modeling for the Versa HD linear accelerator in Monaco, Pinnacle, and Ecli...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984463/ https://www.ncbi.nlm.nih.gov/pubmed/33619852 http://dx.doi.org/10.1002/acm2.13180 |
_version_ | 1783668069378293760 |
---|---|
author | Laub, Wolfram U. Merz, Brandon Kishore, Monica |
author_facet | Laub, Wolfram U. Merz, Brandon Kishore, Monica |
author_sort | Laub, Wolfram U. |
collection | PubMed |
description | In a mixed‐vendor radiation oncology environment, it is advantageous if the department's treatment planning system (TPS) supports the linear accelerators of different vendors. In this publication beam data collection and modeling for the Versa HD linear accelerator in Monaco, Pinnacle, and Eclipse are discussed. In each TPS static field, Intensity‐Modulated Radiation Therapy (IMRT) step and shoot, and Volumetric‐Modulated Arc Therapy (VMAT) plans for flattened and flattening‐filter free photon beams of all available energies were evaluated for field sizes >3 × 3. To compare passing rates, identical beam model validation plans were calculated in each TPS. Eclipse, Monaco, and Pinnacle beam models passed validation measurements in homogeneous materials for a variety of treatment fields, including static, IMRT, and VMAT. In the case of Eclipse, the “dosimetric leaf gap” parameter was found to be critical for passing rates of VMAT plans. The source size parameter plays an important role as well for small fields. In the case of Pinnacle the multileaf collimator offset table needed to be optimized for better VMAT QA results. Each of the investigated treatment planning systems met the criteria to be used clinically in conjunction with Elekta Versa HD linear accelerators. It can be of great advantage to have the option to operate a TPS and linear accelerator from different vendors, as decisions surrounding linear accelerator or TPS purchases are very complicated and not just limited to technical considerations. |
format | Online Article Text |
id | pubmed-7984463 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79844632021-03-25 Commissioning of a Versa HD(TM) linear accelerator for three commercial treatment planning systems Laub, Wolfram U. Merz, Brandon Kishore, Monica J Appl Clin Med Phys Radiation Oncology Physics In a mixed‐vendor radiation oncology environment, it is advantageous if the department's treatment planning system (TPS) supports the linear accelerators of different vendors. In this publication beam data collection and modeling for the Versa HD linear accelerator in Monaco, Pinnacle, and Eclipse are discussed. In each TPS static field, Intensity‐Modulated Radiation Therapy (IMRT) step and shoot, and Volumetric‐Modulated Arc Therapy (VMAT) plans for flattened and flattening‐filter free photon beams of all available energies were evaluated for field sizes >3 × 3. To compare passing rates, identical beam model validation plans were calculated in each TPS. Eclipse, Monaco, and Pinnacle beam models passed validation measurements in homogeneous materials for a variety of treatment fields, including static, IMRT, and VMAT. In the case of Eclipse, the “dosimetric leaf gap” parameter was found to be critical for passing rates of VMAT plans. The source size parameter plays an important role as well for small fields. In the case of Pinnacle the multileaf collimator offset table needed to be optimized for better VMAT QA results. Each of the investigated treatment planning systems met the criteria to be used clinically in conjunction with Elekta Versa HD linear accelerators. It can be of great advantage to have the option to operate a TPS and linear accelerator from different vendors, as decisions surrounding linear accelerator or TPS purchases are very complicated and not just limited to technical considerations. John Wiley and Sons Inc. 2021-02-22 /pmc/articles/PMC7984463/ /pubmed/33619852 http://dx.doi.org/10.1002/acm2.13180 Text en © 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Radiation Oncology Physics Laub, Wolfram U. Merz, Brandon Kishore, Monica Commissioning of a Versa HD(TM) linear accelerator for three commercial treatment planning systems |
title | Commissioning of a Versa HD(TM) linear accelerator for three commercial treatment planning systems |
title_full | Commissioning of a Versa HD(TM) linear accelerator for three commercial treatment planning systems |
title_fullStr | Commissioning of a Versa HD(TM) linear accelerator for three commercial treatment planning systems |
title_full_unstemmed | Commissioning of a Versa HD(TM) linear accelerator for three commercial treatment planning systems |
title_short | Commissioning of a Versa HD(TM) linear accelerator for three commercial treatment planning systems |
title_sort | commissioning of a versa hd(tm) linear accelerator for three commercial treatment planning systems |
topic | Radiation Oncology Physics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984463/ https://www.ncbi.nlm.nih.gov/pubmed/33619852 http://dx.doi.org/10.1002/acm2.13180 |
work_keys_str_mv | AT laubwolframu commissioningofaversahdtmlinearacceleratorforthreecommercialtreatmentplanningsystems AT merzbrandon commissioningofaversahdtmlinearacceleratorforthreecommercialtreatmentplanningsystems AT kishoremonica commissioningofaversahdtmlinearacceleratorforthreecommercialtreatmentplanningsystems |